Verrica Pharmaceuticals Stock Earnings Reports

Verrica reported accelerating commercial traction for YCANTH in Q1 2026 with total revenue of $5.0M (U.S. YCANTH revenue $4.3M, +25% YoY) and 15,302 dispensed applicator units (+51% YoY). Sequential growth was also strong, and March delivered the best monthly unit total since launch with April preliminaries higher still. The company launched a non-dispensing hub (YCANTH Rx) to simplify benefits investigation and fulfillment, is investing in co-pay assistance (noting deductible seasonality in Q1), and plans to staff roughly ~50 sales reps to optimize reach (current territories cover ~85% of TAM). Internationally, Torii/Shionogi launched YCANTH in Japan in February; Verrica retains rights outside Japan and is preparing an EU MAA (no additional Phase III trials required per CHMP feedback). Pipeline progress: the global Phase III program for common warts (COVE-2) is >50% enrolled with COVE-3 targeted to start by mid-2026; Verrica and Torii will split Phase III costs 50/50 with Torii funding the first $40M. VP-315 (basal cell carcinoma) showed compelling Phase II results (97% objective response, 86% mean tumor size reduction, >50% complete histological resolution) and is being readied for Phase III and CMC/clinical supply activities. Financials: GAAP net loss was $9.7M in Q1; non-GAAP net loss $8.8M. Gross product margin ~87%; R&D and SG&A increased due to program and commercial investments. Cash was $20.6M as of March 31, 2026, which management expects will fund operations into Q1 2027. Key near-term value drivers: continued YCANTH adoption and geographic expansion (U.S., EU, Japan), enrollment and readouts from Phase III common warts program, decisions and funding pathway for Phase III VP-315, and potential partnerships to commercialize YCANTH in Europe and broader rights monetization. Primary risk for investors: limited cash runway absent additional financing or partnerships.